New Reach Of Pharma’s Hidden Hand: Hiding In Plain Sight
Big Pharma's influence on patient advocacy groups
June 2023 Cancer Drug Prices Report
The BURDEN of Cancer Drug Prices On Patients. The RELIEF in the Inflation Reduction Act.
NEW REPORT: The Burden Of Cancer Drug Prices On Patients And The Relief The Inflation Reduction Act Provides
New Analysis Shows How The New Law Will Provide Average Savings of $7,590 To Some Cancer Patients With Medicare And Specifically To People Taking Seven High-Priced Cancer Drugs
STATEMENT: After Years Of Advocacy, Patients Will See Long-Awaited Relief From Eli Lilly’s Insulin Price Cut
“It’s Time For The Other Big Insulin Corporations To Follow Suit”
ICYMI: Q&A With P4AD’s Executive Director Merith Basey
Patient Advocate Lisa Ann Wetzel-Trainor Moderated A Conversation Where Merith Answered Questions On Her Background, The Inflation Reduction Act, And P4AD’s Future Goals:
STATEMENT: Unjustified Price Of New ALS Treatment Reinforces Fact That Our Drug Pricing System Fails The People It Is Supposed To Serve – Patients
The following statement was issued by David Mitchell, a cancer patient and founder and president of Patients For Affordable Drugs, in response to the pricing of Relyvrio following the Food and Drug Administration’s approval of the drug combination to treat amyotrophic lateral sclerosis (ALS):
Bob’s Story
My name is Bob Parant, and I have been living with type 1 diabetes for 50 years. I am one of the 3.3 million Medicare beneficiaries who need insulin. I was diagnosed during what I call the “dark ages” of diabetes and have had many challenges along the way, including losing my leg.
Merith Basey Named Executive Director Of Patients For Affordable Drugs
Basey Has Devoted Her Career To Ensuring That Life-saving Medications Are Affordable And Accessible For All Who Need Them
